Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020841 | 1.00 | TLR7 (0.43) | TLR7TLR8NUDT1 | |
| SCHEMBL10237143 | 0.89 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL10237146 | 0.87 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL12020833 | 0.87 | TLR7 (0.44) | TLR7TLR8NUDT1 | |
| SCHEMBL10237142 | 0.86 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL12020701 | 0.84 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL12201375 | 0.84 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL12165176 | 0.81 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL12020795 | 0.81 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL1773748 | 0.78 | TLR7 (0.42) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034938-B2 | Imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a CH( R1) group in the fused ring at 1-position of imidazo ring; modulate immune response, by induction of cytokine biosynthesis or other mechanism | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085895-A1 | Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNG, IL4, IFNAR1 | TLR7 171/4885TLR8 359/4885NUDT1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.